Subcutaneous ketamine in the treatment of depression and suicide risk: case report.
Introduction Several studies have shown that ketamine, an NMDA receptor antagonist, represents a promising alternative in treating depression and suicide. The intranasal or intravenous use of ketamine, currently used, has limitations in terms of cost and complexity. The subcutaneous (SC) route may...
Main Authors: | M. A. Cigognini, D. V. D. Meene |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2023-03-01
|
Series: | European Psychiatry |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823021454/type/journal_article |
Similar Items
-
Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation
by: Ana Paula Anzolin, et al.
Published: (2023-03-01) -
A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression
by: Adem T. Can, et al.
Published: (2022-12-01) -
S-Ketamine in the treatment of depressive emergencies: a cases series of patients in a suicidal crisis
by: B. Baune, et al.
Published: (2022-06-01) -
Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report
by: Minna Chang, et al.
Published: (2024-01-01) -
Effects of ketamine treatment on suicidal ideation: a qualitative study of patients’ accounts following treatment for depression in a UK ketamine clinic
by: Lascelles, K, et al.
Published: (2019)